The completion of patient recruitment removes a key binary risk and de-risks the timeline to a potential blockbuster product. Traders should watch for top-line data in mid-2027 and any partnership or licensing announcements before then. The strong insider buying and RMAT designation support a positive outlook, but the long wait for data means near-term volatility may be limited.
Price Chart
Executive Summary
Mesoblast announced that its Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain due to degenerative disc disease has completed patient recruitment. Top-line results are expected in mid-2027, with a potential FDA filing in Q3 2027. The trial targets a large U.S. market of over 7 million patients, and the drug has RMAT designation, enabling priority review.
Key Facts
- Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain has completed patient recruitment.
- Top-line results expected mid-CY2027; regulatory filing with FDA planned for Q3 CY2027.
- Rexlemestrocel-L has RMAT designation from FDA, providing priority review eligibility.
- Target indication: chronic low back pain due to degenerative disc disease, affecting over 7 million people in the U.S.
- Management estimates potential peak revenue >$10 billion with single-digit market penetration.
- Earlier Phase 3 trial (MSB-DR003) showed clinically meaningful pain reduction and opioid cessation for up to three years.
- Insider buying of $20.8M over the past 30 days (6 buys) aligns with positive sentiment.
Financial Impact
Potential peak revenue >$10 billion with single-digit market penetration; no current revenue from this product.
Risk Factors
- Phase 3 trial may fail to meet primary endpoint, leading to stock decline.
- Regulatory filing and approval are not guaranteed; FDA could request additional data.
- Long timeline to results (mid-2027) means no near-term revenue catalyst.
- Competition from other cell therapies or non-opioid pain treatments could limit market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283366 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.08 (−22.55%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.08 (−22.55%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.08 (−15.38%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.08 (−17.27%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.08 (−3.23%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.08 (−15.89%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.08 (−15.89%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.08 (−8.81%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.08 (−8.81%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.08 (−0.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access